

## **FOR IMMEDIATE RELEASE:**

### **EBI ANNOUNCES COMPLETION OF EA-230 PHASE IA MULTI-DOSE HUMAN SAFETY TRIALS**

**McLean, Virginia, March 10, 2006** – Privately held Exponential Biotherapies, Inc. ("EBI"), a McLean, Virginia based drug discovery and development company, today announced that it has completed a Phase Ia safety trial on its lead drug candidate, a small immunomodulatory peptide designated EA-230.

The study was designed to assess the safety of administering EA-230 to healthy volunteers in multiple doses over a period of time. Subjects received intravenous infusions of the experimental drug three times daily for three days. The dosages used were the same as those previously shown to be safe for single administration. Again, no significant adverse events were found to be associated with the use of the drug. According to Zsolt Harsanyi, Chairman and Chief Executive of EBI, "The importance of demonstrating safety of a drug that might be infused several times over several days cannot be overemphasized." The successful completion of this study should now allow the Company to begin testing for clinical efficacy in patients requiring down-modulation of an over-reactive immune response.

EBI is a privately held, McLean, Virginia based drug discovery and development company with a growing pipeline of novel small molecule drugs designed to treat a wide range of severe inflammatory disorders such as septic shock, radiation sickness and avian influenza. These compounds represent a new class of immune regulating therapeutic agents.

#### **Forward-looking statements**

This press release contains forward looking statements, including statements related to our clinical trials and product candidates. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these or other risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of clinical trials (including our ability to initiate and complete subsequent clinical trials involving EA-230 or any other product candidate); risks that subsequent clinical trials may show EA-230 is not safe and/or effective; issues relating to the intellectual property upon which our drug candidates are dependent; difficulties or delays in obtaining regulatory approval or clearance which are necessary or advisable in the conduct of future clinical trials or are necessary for the commercialization of EA-230 or any of our other product candidates; manufacturing issues relating to EA-230 or any other drug candidate; our ability to obtain financial resources necessary to support our clinical trials, other operations and financial commitments; competitive issues; and other regulatory considerations which affect the business prospects of EBI. Given these and other uncertainties, you should not place undue reliance on these forward-looking statements.

#### **Contact**

Zsolt Harsanyi, Ph.D., Chairman and CEO 703-883-3701